Overview

Study of Abiraterone Acetate, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

This study is to find out whether adding the study drug atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment with abiraterone acetate, prednisone, and Lupron® (leuprolide) is a safe and effective way to treat previously untreated metastatic prostate cancer, and to see whether the study treatment works better than the standard treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

Genentech, Inc.

Treatments:

Abiraterone Acetate
Antibodies, Monoclonal
Atezolizumab
Hormones
Leuprolide
Prednisone